Subtopic Deep Dive
NF-κB Inhibition by Natural Compounds
Research Guide
What is NF-κB Inhibition by Natural Compounds?
NF-κB inhibition by natural compounds examines triptolide and related diterpenes from Tripterygium wilfordii that suppress NF-κB signaling to reduce inflammation and cancer progression.
Research centers on triptolide (PG490), which blocks NF-κB transcriptional activation and IL-2 expression in T-cells (Qiu et al., 1999, 270 citations). Triptolide also inhibits RNA polymerase II, downregulating NF-κB-mediated transcription (Vispé et al., 2009, 180 citations). Over 10 key papers document its effects in pancreatic, lung cancer, and microglial models (Liu et al., 2013, 140 citations; Lee et al., 2002, 119 citations).
Why It Matters
Triptolide sensitizes lung cancer cells to TRAIL-induced apoptosis by blocking NF-κB activation, enhancing chemotherapy efficacy (Lee et al., 2002). In pancreatic cancer, it reverses hypoxia-induced epithelial-mesenchymal transition via NF-κB downregulation, targeting therapy-resistant tumors (Liu et al., 2013). Network pharmacology predicts triptolide targets in rheumatoid arthritis, supporting herbal immunomodulation (Song et al., 2020). These mechanisms inform drug synergies and nanoparticle delivery for hepatocellular carcinoma (Zhang et al., 2018).
Key Research Challenges
Narrow Therapeutic Window
Triptolide's potency causes toxicity, limiting clinical doses despite NF-κB inhibition in cancer models (Wang et al., 2011). Balancing efficacy and safety requires precise dosing studies. Nanoparticle formulations aim to reduce toxicity (Zhang et al., 2018).
Mechanism Specificity
Triptolide inhibits global transcription via RNA Pol II degradation, complicating NF-κB-specific effects (Vispé et al., 2009; Wang et al., 2011). Distinguishing direct NF-κB blockade from broad transcriptional shutdown remains unresolved. Off-target effects hinder targeted therapy development.
Clinical Translation Barriers
Preclinical successes in diabetic cardiomyopathy and rheumatoid arthritis lack human trials (Wen et al., 2013; Song et al., 2020). Variable bioavailability and inflammatory microenvironment interactions impede progression. Synergy predictions need validation beyond network models.
Essential Papers
Immunosuppressant PG490 (Triptolide) Inhibits T-cell Interleukin-2 Expression at the Level of Purine-box/Nuclear Factor of Activated T-cells and NF-κB Transcriptional Activation
Daoming Qiu, Guohua Zhao, Yosuke Aoki et al. · 1999 · Journal of Biological Chemistry · 270 citations
PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes ...
Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA
Stéphane Vispé, Luc DeVries, Laurent Créancier et al. · 2009 · Molecular Cancer Therapeutics · 180 citations
Abstract Triptolide, a natural product extracted from the Chinese plant Tripterygium wilfordii, possesses antitumor properties. Despite numerous reports showing the proapoptotic capacity and the in...
Triptolide reverses hypoxia‐induced epithelial–mesenchymal transition and stem‐like features in pancreatic cancer by NF‐κB downregulation
Li Liu, Alexei V. Salnikov, Nathalie Bauer et al. · 2013 · International Journal of Cancer · 140 citations
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignancies characterized by an intense tumor stroma with hypoperfused regions, a significant inflammatory response and pronounced ...
Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-κB activation
Kye Young Lee, Jae Seuk Park, Young‐Koo Jee et al. · 2002 · Experimental & Molecular Medicine · 119 citations
TNF-related apoptosis-inducing ligand (TRAIL/Apo- 2L), a newly identified member of the TNF family promotes apoptosis by binding to the transmembrane receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5). TRAI...
Triptolide (TPL) Inhibits Global Transcription by Inducing Proteasome-Dependent Degradation of RNA Polymerase II (Pol II)
Ying Wang, Jin‐Jian Lu, Li He et al. · 2011 · PLoS ONE · 111 citations
Triptolide (TPL), a key biologically active component of the Chinese medicinal herb Tripterygium wilfordii Hook. f., has potent anti-inflammation and anti-cancer activities. Its anti-proliferative ...
Triptolide-induced Cell Death in Pancreatic Cancer Is Mediated by O-GlcNAc Modification of Transcription Factor Sp1
Sulagna Banerjee, Veena Sangwan, Olivia McGinn et al. · 2013 · Journal of Biological Chemistry · 110 citations
Prediction of triptolide targets in rheumatoid arthritis using network pharmacology and molecular docking
Xinqiang Song, Yu Zhang, Erqin Dai et al. · 2020 · International Immunopharmacology · 95 citations
Reading Guide
Foundational Papers
Start with Qiu et al. (1999, 270 citations) for core NF-κB and IL-2 inhibition mechanism in T-cells; follow with Vispé et al. (2009, 180 citations) for transcription-level effects and Lee et al. (2002, 119 citations) for cancer sensitization.
Recent Advances
Study Liu et al. (2013, 140 citations) on pancreatic cancer EMT; Song et al. (2020, 95 citations) for rheumatoid arthritis targets; Zhang et al. (2018, 90 citations) for nanoparticle delivery advances.
Core Methods
Core techniques: luciferase reporter assays for NF-κB activity (Qiu et al., 1999); RNA Pol II ubiquitination Western blots (Wang et al., 2011); network pharmacology with molecular docking (Song et al., 2020).
How PapersFlow Helps You Research NF-κB Inhibition by Natural Compounds
Discover & Search
Research Agent uses citationGraph on Qiu et al. (1999) to map 270-citation network of triptolide-NF-κB studies, revealing clusters in cancer and inflammation. exaSearch queries 'triptolide NF-κB pancreatic cancer' for 50+ related papers beyond OpenAlex. findSimilarPapers on Liu et al. (2013) uncovers hypoxia-EMT analogs.
Analyze & Verify
Analysis Agent runs readPaperContent on Vispé et al. (2009) to extract RNA Pol II degradation data, then verifyResponse with CoVe against Wang et al. (2011) for mechanism consistency. runPythonAnalysis plots dose-response curves from triptolide apoptosis assays using pandas, with GRADE scoring evidence strength for NF-κB specificity.
Synthesize & Write
Synthesis Agent detects gaps in triptolide clinical translation via contradiction flagging between preclinical efficacy (Liu et al., 2013) and toxicity reports. Writing Agent applies latexSyncCitations to compile reviews with 10+ papers, latexCompile for publication-ready PDFs, and exportMermaid for NF-κB signaling diagrams.
Use Cases
"Extract triptolide dose-response data from pancreatic cancer papers and plot IC50 curves"
Research Agent → searchPapers('triptolide NF-κB pancreatic') → Analysis Agent → readPaperContent (Liu et al., 2013; Banerjee et al., 2013) → runPythonAnalysis (pandas curve fitting, matplotlib IC50 plot) → researcher gets CSV-exported survival curves with statistical fits.
"Write LaTeX review on triptolide NF-κB inhibition mechanisms with citations"
Synthesis Agent → gap detection (pre- vs post-2015 papers) → Writing Agent → latexEditText (mechanism outline) → latexSyncCitations (Qiu 1999, Vispé 2009) → latexCompile → researcher gets compiled PDF with synced bibliography and NF-κB pathway figure.
"Find GitHub repos analyzing triptolide network pharmacology data"
Research Agent → searchPapers('triptolide network pharmacology') → paperExtractUrls (Song et al., 2020) → paperFindGithubRepo → githubRepoInspect → researcher gets repo code for molecular docking simulations and validated NF-κB target predictions.
Automated Workflows
Deep Research workflow scans 50+ triptolide papers via searchPapers → citationGraph → structured report on NF-κB inhibition across diseases. DeepScan applies 7-step analysis: readPaperContent (Qiu 1999) → CoVe verification → runPythonAnalysis on transcription data → GRADE scoring for evidence synthesis. Theorizer generates hypotheses on triptolide-TRAIL synergies from Lee et al. (2002) and Liu et al. (2013).
Frequently Asked Questions
What defines NF-κB inhibition by natural compounds?
It focuses on triptolide from Tripterygium wilfordii suppressing NF-κB transcriptional activation and downstream inflammation (Qiu et al., 1999).
What are key methods for studying triptolide's effects?
Methods include IL-2 expression assays in PMA-stimulated T-cells, RNA Pol II degradation analysis, and NF-κB luciferase reporter assays (Qiu et al., 1999; Vispé et al., 2009; Wang et al., 2011).
What are the most cited papers?
Qiu et al. (1999, 270 citations) on T-cell IL-2 inhibition; Vispé et al. (2009, 180 citations) on transcription blockade; Liu et al. (2013, 140 citations) on pancreatic cancer EMT reversal.
What open problems exist?
Challenges include toxicity reduction, NF-κB-specific targeting amid global transcription inhibition, and clinical validation of network-predicted targets (Wang et al., 2011; Song et al., 2020).
Research Natural Compounds in Disease Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching NF-κB Inhibition by Natural Compounds with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers